Primary Progressive MS (PPMS). Please help with some important research by the Menzies Institute for Medical Research in Tasmania

Menzies Institute for Medical Research  Multiple Sclerosis Research

Menzies Institute for Medical Research Multiple Sclerosis Research

What is the Aim of the Project?

While there are now a number of immunotherapy treatments available for people with Relapsing Remitting MS (RRMS), little progress has been made on treatments for people with Primary Progressive MS (PPMS). Understanding the causes of PPMS and what affects its progress over time can ultimately lead to treatments and prevention.

There is very little evidence available on how risk factors operate differently in people with PPMS compared to people with a RRMS onset, but there are some clues to suggest that there are differences. For example, the latitudinal gradient is less strong in PPMS compared to relapsing remitting MS, and a similar number of females have PPMS compared to males, while far more women than men have the relapsing remitting type of MS.

This project has two phases:

Phase 1 – The aim is to clarify which factors might contribute to the onset of PPMS. We will compare possible factors among a large group of people with PPMS to a large group of people without MS.

Phase 2 – The aim is to learn about factors that might influence the progression of PPMS over several years. We will follow a large group of people with PPMS over time.

The research team has conducted similar studies in people with MS, including all types of MS, but the number of people with PPMS (1 in 10) was not enough to conduct a separate analyses on this group. In this project we plan to include 350 people with PPMS.

Who are the Researchers for this Project?

This research is being led by Associate Professor Ingrid van der Mei and Professor Bruce Taylor who are senior and experienced researchers in the epidemiology of MS at the Menzies Institute for Medical Research, Hobart, Tasmania. Other investigators involved are Professor Anne-Louise Ponsonby from the Murdoch Childrens Research Institute in Melbourne, Professor Robyn Lucas from the National Centre for Epidemiology and Population Health in Canberra, Dr Steve Simpson (post-doctoral research fellow) from the Menzies and Associate Professor Leigh Blizzard (biostatistician) from the Menzies. The team has worked together for many years on a number of MS studies.

Who is eligible to help with this MS research?

The project is currently calling for Australian residents with PPMS, aged between 18-59 years, as our group of people without MS are of that age. However, we will extend the age range to 60 years or older for the longitudinal study in the near future. Please register your interest for the study by providing your contact details and signing the Statement of Informed Consent.

How is this project funded?

Phase 1 of the project is funded by MS Research Australia, and we are seeking funding to follow participants in the future for Phase 2 of the project.

What happens if I volunteer?

We will ask you about a range of lifestyle and other factors including for example your medical history, employment, where you have lived, and dietary intake. We will also ask you about your symptoms, quality of life and any disability caused by your MS.

In Phase 1, part of this information will be asked by two questionnaires that will be mailed to you and part of the information will be asked via a phone interview. The phone interview will take about 1 hour.

In Phase 2, we will ask for information by online questionnaires, or if you prefer via phone interview.

We will also ask you to visit a local pathology service for a blood sample. This will be used to look at markers that might be related to PPMS, including viral and vitamin D markers. Part of the blood will be used to extract DNA to examine which genetic markers might be associated with PPMS. If you have previously participated in a genetic study as part of the Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), we will ask your permission to use the ANZgene data for our study.

Your blood sample and the DNA extracted from it will not, without your consent, be released for uses other than to identify genetic markers that may be associated with the onset and progression of MS.

 

It is possible this study may incidentally reveal that you have a predisposition to a genetic disorder important to your future heath. This is an unlikely event, but if it did occur we will advise you and offer to arrange genetic counselling.

Participation in this study is voluntary. It is completely up to you whether or not you participate in Phase 1 and Phase 2. If you decide not to participate, it will not affect the treatment you receive now or in the future. If you decide to participate, you may withdraw your consent at any time.

Reimbursement for your costs

You will not be paid for your participation in this project. However, you will be reimbursed if you require special transport as a result of participation, i.e. taxi voucher.

Possible Risks and Benefits

We cannot guarantee or promise that you will receive any personal benefits from this project other than an indirect benefit through the advancement of our knowledge of PPMS.

There are no risks to participating other than the inconvenience/discomfort of providing a blood sample. There is a small risk that this will result in some temporary bruising, redness or swelling.

Privacy, Confidentiality and Disclosure of Information

All questionnaire and phone information sourced from you will be kept secure and confidential. Only people involved in the study will have access to the study data. Data will be stored on secure servers at the Menzies Institute for Medical Research. Personal information can only be disclosed with your permission or if required by law, and you have the right to access information collected and stored by the researchers about you. Participants will not be identified in any publication. All blood samples will be privacy-coded and laboratory staff conducting the blood tests will not know names of participants.

Results of Project

The results of the project will be published in peer-reviewed medical journals. These medical journal reports, together with other information, will be used to provide up-to-date policy and advice about optimal prevention and medical care for MS.

Further Information and Ethical issues

This project will be carried out according to the National Statement on Ethical Conduct in Human Research 2007 produced by the National Health and Medical Research Council of Australia. The project has been approved by the Tasmanian Human Research Ethics Committee (Tasmania) Network (Reference Number: H0014794). If you have any concerns of an ethical nature or complaints about the manner in which the project is conducted, you may contact the Executive Officer of the Tasmanian Human Research Ethics Committee (Tasmania) Network on (03) 6226 7479 or human.ethics@utas.edu.au.

If you require further information or if you have any concerns about the project you can contact:

 

PPMS Study Officer

Susan Dobson ppms.study@utas.edu.au

03 6226 4269

or

 

Multiple Sclerosis Research – Are you a Parent with MS who has a child aged 9-12 years? Please help Maria Hadji-Michael with her doctoral research.


 Multiple Sclerosis Research

Multiple Sclerosis Research

Maria Hadji-Michael has asked us to help her promoted some research she is conducting with people who have MS and have children aged between 9 and 12.

She writes “As part of my Doctorate in Clinical Psychology I am looking for healthy families with children aged 9-12 years to take part in my simple questionnaire – based study. I am investigating how children who have a parent affected by MS cope in families and compare the results to families where both parents are unaffected by illness.

If you decide to take part, you would be asked to simply complete some questionnaires, your spouse/ partner will complete some and also your child will complete their own set. These questionnaires would take no longer than 15 mins per family member and I will provide you with a stamped address envelop for you to post them back to me directly.

My research has obtained full ethical approval from the NHS research ethics committee and all your information will be kept securely and in confidence.


The research is valuable and important, as it will help identify the needs of young children who have a parent with an illness and in this way enable clinicians to design and implement services to address these needs in the future. If you can help me out with this research project please let me know and I will send you the consent forms and questionnaires. Thank you in advance for your help.

Please send me a message over Facebook or via email maria.c.hadjimichael@gmail.com

Maria Hadji-Michael

Not just another Multiple Sclerosis Survey – help a clinical psychologist with MS at the University of Pretoria, with her research


University of Pretoria - Multiple Sclerosis Research

University of Pretoria – Multiple Sclerosis Research

Isabelle Swanepoel, a clinical psychologist and lecturer at the University of Pretoria, South Africa.

She says of herself “I am currently busy with my PhD study in MS, I myself was diagnosed in 2004 and has been blessed with good health. This is not just another MS survey, using the members and moving on. I have MS myself and therefor know the experience and the journey. I want to make a difference and I believe I will. ”

Swanepoel invites you to help her with that research by taking part in her survey.  She says ” Dear fellow MS Experts – by – Experience

I was diagnosed with MS (RR) in 2004 and have been blessed for the last 10 years. From my hospital bed in 2004 I made a promise to myself that I will help other with MS in this struggle…
Today 10 years and 2 beautiful kids later, my dream, promise and vision is coming true!!!
I am currently busy with my PhD study in MS and the results will be used internationally to help and improve the lives of fellow MS survivors all over the world. I realize that the MS community is tired of being used for research; however this is not the same. This is for US.

I am not ignorant for all the criticism and judgement that may follow… staying positive.

I have a gut feel that I can be supported in getting this message through to MS survivors, that nothing can stop us from health!
Waiting in anticipation to hear from you how I can take this journey forward.
Isabelle

https://www.surveymonkey.com/s/FB32T9K

Thanks in advance.  Please use the comment box below to ask Ms Swanepoel  any questions about the research.


“Killer T cells” – a new way to fight Multiple Sclerosis. Read our interview with Gary Allen one of the test subjects for Prof Michael Pender MS research!


Gary Allen Multiple Sclerosis

Gary Allen Multiple Sclerosis

PatientTalk.Org have just completed perhaps the most important interview in the blog’s history.  Today we interview Mr Gary Allen.  Gary has been a participant in some of the most encouraging research into multiple sclerosis for some years.

In the interview below Gary tells us about his multiple sclerosis and his role as a “guinea pig” in the research of Prof Michael Pender of the  QIMR Berghofer Medical Research Institute.  He tells how being part of the research has been significant improvements on his pain levels, feelings of fatigue and general cognition.

You can check out more about the research at http://msqld.org.au/homepage/latest-news/808-prof-pender-research-update

 

a)      Please describe the story of your initial diagnosis and symptoms of MS?

I had what we now know was my first MS episode in 1994.  I had terrible motion sickness and nausea, lost control of some of my facial muscles and had some reduced power in my legs.  At the time there were a number of possible diagnoses, so when I recovered I got on with my life.  It wasn’t until 2000 when I had another major episode that I was clinically diagnosed with relapsing remitting ms.  In 2004 my MS went progressive.

b)      How did the MS progress?

During the last 10 years my symptoms have… well, progressed.  I slowly went from walking with a stick, to a crutch, to furniture walking and using a wheelchair for longer distances, to pretty much being in a wheelchair all the time, and then needing a hoist for transfers.  I have no real touch or temperature sensation in my legs or arms.  I also have intention tremors and lack of dexterity in my hands.  My legs reached a point where they have very little voluntary movement but my involuntary reflex / spasms were ‘brisk’ (a term that doesn’t do it justice).  The spasms can be painful and I had just started to experience the ‘lightning strike’ pain around my head before the treatment started.  I also would get long periods of painful pins and needles in my hands and face.  Looking back, I was really struggling with fatigue, concentration and cognition issues, which I didn’t notice because it crept up on me.  All of which was impacting on my working life (I have continued to be very busy with two plus jobs… yes I am a self-confessed workaholic), time with my family and my social life.

c)       Does the Queensland climate affect your MS?

Like many people living with MS, I have a certain degree of heat intolerance – so my symptoms become more pronounced as it gets hotter.  Consequently Brisbane’s 68-82 degree F average in Summer and subtropical humidity can be a real challenge.  At the age of 18 I moved from the grey and wet joys of England to Queensland, so you can imagine what a effortless transition in climate it was for me.  <chuckle>  Fortunately we have air conditioning at home so we can keep me reasonably cool.

d)      Please can you introduce our readers to Prof Michael Pender’s treatment and research?

Back in 2004 (or thereabouts) Prof Pender theorised that the Epstein Barr virus (a common cause of glandular fever) was mutating the B cells of people with MS.  As a consequence the virus was remaining in their systems – building up in the brain and spine.  This was also responsible for the body attacking the brain and spine column causing the implication and damage associated with the progression of MS.  More recently he’s been working with an oncology researcher at QIMR Berghofer Medical Research Institute. In 2013 Michael took 400ml of my blood, prompted it to develop ‘killer T Cells’ that eradicated EBV from my B cells.  Because I was the ‘first human guinea pig’, they reinfused my cells over 4 visits in a 6 week period.  Because I was first, we really had no idea of what to expect, but inside the first 2 weeks the results were astonishing.

e)      How did you hear about it?

I donated some blood to Prof Pender’s research back in 2000.  It turns out that I was an excellent candidate for the treatment (having lots of EBV infected cells and almost no EB antibodies).  So in 2012 Michael visited me a couple of times to meet with me and my wife to discuss the treatment.  It was something of a jump in the dark, with there not being any previous patients with MS receiving the treatment.  The science looked excellent (I read research proposals for a living) but essentially it boiled down to: we think it will put a handbrake on the progression, but it might cause you to have a massive attack.  Frankly 10 years into progression and no real treatment available, I had the attitude that it was well worth a punt.  Looking back I am just so grateful for having had the opportunity, delighted we made the right decision, and very conscious of my responsibility to get the message out there that there is a light at the end of the tunnel for families struggling with progressive MS.  I want to do what I can to help make a clinical trial a reality.  The extra lumbar punctures and MRIs I’ve had to help collect data to make the case for a trial is the smallest of  asks.

f)       Can you describe the procedure to us?

It took around 4 weeks to ‘grow’ the killer T cells and do the lab testing.  The cells were returned into my system via four infusions over a 6 week period.  It was done this way so I could be closely monitored for adverse reactions / side effects.  Following the treatment I returned to the ward several times for tests and neurological assessments. Next month I am due to have my (12 months on) lumbar puncture and MRI.

g)      What were the outcomes negative and positive?

In less than 2 weeks we started seeing very positive outcomes.  At first I was very conscious of the potential for the placebo effect, but the positives kept building, and have been sustained for a year.  I have a remarkable change to my fatigue, cognition and memory.  I have a significant improvement in pain levels (which is pretty much gone) and marked improvement in the size and duration of pins-and-needle discomfort.  I saw a reduction in painful legs spasms and my intention tremor has in my left hand has reduced.  I work as a policy officer at Griffith University and went from struggling through the delivery of three workshops a year to delivering one or two per week.   I have a very nerdy indicator of the improvements: Prior to 2007 I could score up to 97 planes landed in the iPad game Flight Control.  After 2007 I gave up playing because I couldn’t land more than 14.  Two weeks after starting the treatment I got 117.  In May last year I landed 561!  At which point my wife gently observed that it might be time for a different challenge.  🙂  Last month my wife, son and I went on our first long holiday together in more than 10 years.  I have the energy and enthusiasm to play with my boy.  We’ve noticed some increase in voluntary movement in my legs – not much and we’re trying to work out now how much of that is because muscle shortening and atrophy.  It was exciting when the scans and tests started to echo my lived experience.  My MRI, (pre, during and post) went from showing four areas of my brain under attack to 2 and those 2 areas were 40% the size of what they were.  The next scan results are going to be very interesting.  I am yet to experience any side effect or negative outcome.

h)      What do you think the future for the technique is?

MS Queensland is trying to raise AU$400,000 to conduct a clinical trial.  That will provide more data about the effectiveness and safety of the treatment and is the first step in registering the testament with the Australian TGA.  Ironically one of the of the things that attracted me to the treatment – the fact it involves no drug, no stem cells, just my own cells returned to me – also now is the funding challenge, there’s no drug for a pharmaceutical company to commercialise.

i)        What is the prognosis of your multiple sclerosis?

Because I am the first guinea pig we  have no idea how long this will last, whether it will need to be ‘topped up’ or what it means for my long-term prognosis.  What I can say is that I have been blessed with an amazing year with no progression, some tangible improvements and perhaps the greatest gift of all: Hope.

 

j)        Have you any advice for somebody just diagnosed with multiple sclerosis?

Oooo how much space do I have?  <chuckle>.  Perhaps 3 things:

  1. There really is reason to hope.  An effective treatment is within reach.
  2. Keep up with your physio, stretches and working those muscles because you don’t want to be like me now wondering whether, if I’d practised what I’m preaching now, my legs maybe could be doing more.
  3. Always remember that accepting help, whether it’s in the form of pain management or other medication, counselling, a wheelchair or whatever isn’t giving up or admitting how bad things might go for you… it’s just help, and if it means you can cope better or can go out and about, it’s worth it!

k)      What is, in  your view, the future of Prof Pender’s research?

Michael believes that the theory and treatment works for early diagnosis relapsing remitting patients – i.e. at some point soon it will stop the damage before it happens.  Now if that doesn’t take your breath away I don’t know what will.

To help raise money for a clinical trial my wonderful wife Renay is conducting a short story competition where the entry fee is donated to the Society.  Go to http://www.renayallen.com/community-2/ to find out more and to enter the competition.